Navigation Links
PhRMA Statement on Expansion of SCHIP
Date:2/4/2009

WASHINGTON, Feb. 4 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today regarding the State Children's Health Insurance Program Reauthorization Act:

"President Obama's signing into law an expansion of the State Children's Health Insurance Program (SCHIP) marks a tremendous victory for millions of low-income, uninsured American families and, indeed, for all Americans -- for we are the friends and neighbors of those who will be helped.

"SCHIP is a vital resource for children and families across America and has provided high-quality, comprehensive health insurance coverage to more than seven million low-income children in the past year alone. It provides children important access to quality health care and, with it, peace of mind for their families. That's why PhRMA has long supported reauthorization of SCHIP, and that's why we are pleased that it has been signed into law.

"What's more, the bill signed by President Obama will extend access to SCHIP coverage to an additional 4.1 million children who would otherwise be uninsured. This is an important step toward the goal of helping all American children have access to the high-quality, affordable health care they need.

"In fact, a recent announcement from the Department of Health and Human Services shows how effective SCHIP is at providing care to low-income children. According to HHS, 7.4 million children were enrolled in SCHIP in 2008, a 4 percent increase over the previous year.

"This is important progress, as a healthy child is more likely to be a healthy adult, and SCHIP provides essential resources to keep children healthy.

"Such challenges will only increase in the future if we don't take steps to confront it now. According to the Centers for Disease Control and Prevention, the share of children who are overweight has more than tripled in the U.S. over the last three decades. Other estimates suggest that by 2015, 24 percent of children in the U.S. will be overweight or obese. This reality leads to additional problems: a recent study predicted that one in three children born in 2000 will develop diabetes over the course of his or her life.

"That's why PhRMA is a proud member of the Partnership to Fight Chronic Disease, and that's why we applaud the efforts of Congress and President Obama to make this victory happen. Every child deserves a chance to be healthy, and SCHIP will help to provide that opportunity."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on the dangers of imported drugs, visit: http://www.buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PhRMA Statement on Enactment of FDA Legislation
2. PhRMA Celebrates 20th Anniversary of Discoverers Award
3. PhRMA Applauds House Committee on Foreign Affairs Commitment to Continuing Efforts to Fight AIDS, Tuberculosis, and Malaria Epidemics
4. Richard T. Clark Elected PhRMA Board Chairman
5. PhRMA Revised Marketing Code Reinforces Commitment to Responsible Interactions With Healthcare Professionals
6. Johnson & Johnson Announces Commitment To Adopt Revised PhRMA Marketing Code for Responsible Interactions With Healthcare Professionals
7. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
8. Revised PhRMA Marketing Code Calls for More Educational Materials for Health Care Providers and Staff - Anatstat Health Education Can Help
9. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
10. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
11. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Dr. Edward Hebert is celebrating ... imagine doing anything else,” said Dr. Hebert. “I count my blessings daily for the ... with my patients is what I look forward to the most. The relationships I ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Grandpa's Visit”: a tender and ... share with the others. “Grandpa's Visit” is the creation of published author, Beverly Brumfield, ... is much like the character in her book. She shares, “Mr. Rice is struggling ...
(Date:9/25/2017)... ... , ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the ... drinks, with the new NEXTY Gold Award at the Natural Products Expo East trade ... which is reserved for just those companies that hit high marks on the criteria ...
(Date:9/25/2017)... ... September 25, 2017 , ... Emerald Ash Borers kill Ash trees in as ... throughout the Philadelphia region. A video by Rob Nagy, ISA Certified Arborist at Giroud ... While several are dead or showing signs of decline from Emerald Ash Borers, two ...
(Date:9/24/2017)... ... ... Andrea Purcell, NMD, had an epiphany one evening. Four months pregnant, she sat sobbing at ... pregnancy was so hard. She wondered why no one talks about what it is really ... she decided to write what she wished her friends and colleagues could have told her: ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s annual ... guide to the latest innovations happening across the industry. ... publication to focus on providing a comprehensive look at ... issue covers the most innovative companies, startups, divisions, products, ... "Everyone in this industry wants ...
Breaking Medicine Technology: